Intermittent Explosive Disorder Completed Phase 2 Trials for Fluoxetine (DB00472)

IndicationStatusPhase
DBCOND0030738 (Intermittent Explosive Disorder)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00078754A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive DisorderTreatment